title: Role of subcutaneous apomorphine in parkinsonian voiding dysfunction.
abstract: Ten patients with Parkinson's disease and urinary symptoms underwent urodynamic assessments before and after subcutaneous administration of the dopamine receptor agonist apomorphine. Voiding efficiency improved after apomorphine injection, with an increase in mean and maximum flow rates in nine patients and reduction in post-micturition residual volume in six. Although the effect on detrusor behaviour was variable, subcutaneous apomorphine may be of use in both the assessment and treatment of voiding dysfunction in patients with Parkinson's disease.
authors.affiliation: Department of Urology, Middlesex Hospital, London.
authors.forename: T J
authors.initials: TJ
authors.lastname: Christmas
authors.forename: P A
authors.initials: PA
authors.lastname: Kempster
authors.forename: C R
authors.initials: CR
authors.lastname: Chapple
authors.forename: J P
authors.initials: JP
authors.lastname: Frankel
authors.forename: A J
authors.initials: AJ
authors.lastname: Lees
authors.forename: G M
authors.initials: GM
authors.lastname: Stern
authors.forename: E J
authors.initials: EJ
authors.lastname: Milroy
mesh_terms: D000328:Adult; D000368:Aged; D001058:Apomorphine / Q000008:administration & dosage* / Q000009:adverse effects; D004294:Domperidone / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007279:Injections, Subcutaneous; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000150:complications*; D001743:Urinary Bladder / Q000502:physiology; D014555:Urination Disorders / Q000188:drug therapy* / Q000209:etiology; D014563:Urodynamics / Q000187:drug effects
chemical_list: D004294:Domperidone; D001058:Apomorphine